Immune System Key Ltd.

Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.

LATEST NEWS

Harvard medical school and ISK Ltd submitted a grant application for a clinical trial with Alzheimer’s patients

13 Apr|Comments Off on Harvard medical school and ISK Ltd submitted a grant application for a clinical trial with Alzheimer’s patients

ISK Ltd and Harvard medical school submitted together grant application to support phase 1B clinical trial for treatment of Alzheimer’s disease.

  • Usylvester

PHASE 1B/2A Clinical trial started

13 Apr|Comments Off on PHASE 1B/2A Clinical trial started

The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

09 Jan|Comments Off on ISK received the FDA’s approval to start Phase 1b/2a with AML patients

  • Harvard-Logo

Cooperation with Harvard Medical School (MGH)

27 Oct|Comments Off on Cooperation with Harvard Medical School (MGH)

ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases